Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN3017 in relapsed/refractory CD30+ lymphomas
NCT06018129Phase 2Terminated
- Sponsor
- Genmab
- Start
- Sep 2023
- Primary completion
- Feb 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of gen3017 in classical Hodgkin lymphoma (cHL), T-cell lymphoma, sponsored by Genmab. Started Sep 2023; status: terminated.
02
Drugs
gen3017
03
Conditions
classical Hodgkin lymphoma (cHL)T-cell lymphoma
Beyond the preview
Go deeper on NCT06018129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06018129.